Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?

de Melo Gagliato D, Chavez-MacGregor M.

Ann Surg Oncol. 2018 Jul;25(7):1786-1787. doi: 10.1245/s10434-018-6415-8. Epub 2018 Mar 29. No abstract available.


Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R.

Clin Cancer Res. 2018 Apr 15;24(8):1785-1794. doi: 10.1158/1078-0432.CCR-17-1970. Epub 2017 Dec 6. Review.


Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

de Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, Holgado E.

Biochim Biophys Acta. 2017 Dec;1868(2):527-537. doi: 10.1016/j.bbcan.2017.10.003. Epub 2017 Oct 20. Review.


Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.


Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.

de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN.

Oncotarget. 2016 Sep 27;7(39):64431-64446. doi: 10.18632/oncotarget.7043. Review.


Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.

Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F.

Am J Clin Pathol. 2015 Nov;144(5):713-21. doi: 10.1309/AJCPWDEQYCYC92JQ.


Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience.

da Fonseca LG, de Melo Gagliato D, Takahashi TK, Mak MP, Barroso-Sousa R, Testa L, Helena VP, de Paula Costa R, Hoff PM, Mano MS.

Breast Care (Basel). 2014 Apr;9(4):255-60. doi: 10.1159/000365950.


MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Genitourin Cancer. 2015 Feb;13(1):e19-26. doi: 10.1016/j.clgc.2014.06.017. Epub 2014 Jul 3.


Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS.

Clin Breast Cancer. 2014 Dec;14(6):468-74. doi: 10.1016/j.clbc.2014.06.001. Epub 2014 Jun 23.


MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.

Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS.

Oncotarget. 2014 Apr 15;5(7):1837-45.


Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes.

Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM.

Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):316-23. doi: 10.1158/1055-9965.EPI-13-0929. Epub 2013 Dec 2.


Biological therapies in breast cancer: common toxicities and management strategies.

Barroso-Sousa R, Santana IA, Testa L, de Melo Gagliato D, Mano MS.

Breast. 2013 Dec;22(6):1009-18. doi: 10.1016/j.breast.2013.09.009. Epub 2013 Oct 19. Review.


Supplemental Content

Loading ...
Support Center